Drug intelligence / Profile preview

Flustop

Development stage: Unknown
Lead developer: CAPS Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Flustop** is a CAPS Pharmaceuticals oral fixed-dose cold-and-flu symptom-relief capsule marketed in Zimbabwe. The manufacturer lists paracetamol, phenylephrine, and diphenhydramine hydrochloride as active ingredients. Paracetamol provides analgesic and antipyretic activity; phenylephrine is a sympathomimetic nasal decongestant; and diphenhydramine is a sedating first-generation H1 antihistamine intended to relieve allergy-associated symptoms such as sneezing. It is marketed for symptomatic relief of flu and common-cold symptoms rather than as a direct antiviral treatment. ([caps.co.zw](https://caps.co.zw/products/flustop/))

Brand names: Flustop

Targets

COXADRA1A (α1A)ADOR (Adenosine receptors)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Flustop.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flustop.

Explore the full profile